Entheon Biomedical Corp. provide an update on its Observational Study, EBIQ-101. The results of EBIQ-101 will serve as the foundation for the strategic aims of Entheon IQTM and Entheon IDTM, the development of a framework for characterizing the psychedelic drug state of patients, and to research phenotypes associated with particular addictions and mental health disorders.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.16 CAD | 0.00% | -30.43% | +60.00% |
Apr. 18 | Entheon Biomedical Corp. announced that it has received CAD 0.1475 million in funding | CI |
Apr. 11 | Entheon Biomedical Corp. announced that it expects to receive CAD 0.1475 million in funding | CI |
1st Jan change | Capi. | |
---|---|---|
+60.00% | 1.04M | |
+2.42% | 42.75B | |
+47.70% | 41.61B | |
+12.09% | 41.34B | |
-8.83% | 26.59B | |
+6.84% | 25.49B | |
-22.84% | 18.12B | |
+30.41% | 12.24B | |
-2.08% | 11.76B | |
+9.14% | 11B |
- Stock Market
- Equities
- ENBI Stock
- News Entheon Biomedical Corp.
- Entheon Biomedical Corp. Announces EBIQ-101 First-Patient Dose